TP53 and neoplasm: Thus, this analysis makes it possible to assign patients to four prognostic groups that can be considered surrogates of TCGA groups, such as ultramutated DNA polymerase-ε (POLE) with the best prognosis, MSI or mismatch repair deficient (MMRd) hypermutated neoplasms with an intermediate prognosis, p53 abnormal tumours with the worst prognosis, and tumours with copy-number low alterations with a good prognosis [56,57,58].